BackPropanc Biopharma Overview

Propanc Biopharma Long Term Debt

Track Propanc Biopharma's long-term debt ($1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1.03M
↑ 997.04% YoYΔ $936353.00 vs prior year quarter

Peer trimmed avg / median

Loading

Propanc Biopharma Long Term Debt History

Loading

Propanc Biopharma vs. peers: Long Term Debt Comparison

Loading

Propanc Biopharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Propanc Biopharma (PPCB) FAQ

The latest long-term debt for PPCB is $1M as of March 2026. That compares with $94K in the prior-year period — up 997.0% year over year. Investors often review this figure alongside Propanc Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, PPCB's long-term debt moved from $94K to $1M — a 997.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Propanc Biopharma's operating scale or balance-sheet position.

A long-term debt figure of $1M for PPCB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting PPCB's long-term debt ($1M), review year-over-year change from $94K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Propanc Biopharma's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.